Mizuho upgraded Medtronic (NYSE:MDT) to a “strong-buy” rating, contributing to a “Moderate Buy” consensus among analysts with a $111.05 price target. The upgrade follows Medtronic’s beat on Q3 earnings expectations and positive FY2026 guidance, driven by strong demand for heart devices. Despite overall positive sentiment from some analysts highlighting growth potential in cardiovascular and robotics, others express mixed views, trimming price targets due to legal and competitive challenges.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Medtronic (NYSE:MDT) Upgraded by Mizuho to "Strong-Buy" Rating
Mizuho upgraded Medtronic (NYSE:MDT) to a “strong-buy” rating, contributing to a “Moderate Buy” consensus among analysts with a $111.05 price target. The upgrade follows Medtronic’s beat on Q3 earnings expectations and positive FY2026 guidance, driven by strong demand for heart devices. Despite overall positive sentiment from some analysts highlighting growth potential in cardiovascular and robotics, others express mixed views, trimming price targets due to legal and competitive challenges.